Trends in the Treatment and Survival of Pancreatic Cancer: Analysis of 23,339 Patients Diagnosed Between 2010 and 2017

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-09-19 DOI:10.1002/cam4.71248

Marko Damm, Miriam Heinig, Jonas Rosendahl, Patrick Michl, Ulrike Haug, Sebastian Krug

{"title":"Trends in the Treatment and Survival of Pancreatic Cancer: Analysis of 23,339 Patients Diagnosed Between 2010 and 2017","authors":"Marko Damm, Miriam Heinig, Jonas Rosendahl, Patrick Michl, Ulrike Haug, Sebastian Krug","doi":"10.1002/cam4.71248","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>With a rising incidence and unchanged poor prognosis, pancreatic cancer is increasingly becoming a focus of gastroenterological oncology, but there is a lack of real-world data. The aim of the current study was to investigate trends in survival and treatment patterns by analyzing German health claims data.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Pancreatic cancer patients diagnosed between 2010 and 2017 were identified from the German Pharmacoepidemiological Research Database (GePaRD, approximately 20% of the German population). Data on demographics, tumor treatment within 1 year after diagnosis, and survival were extracted.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study population comprised 23,339 patients with a median age of 74 years (IQR 66–80) and 44% with localized and 56% with metastatic disease. Overall, 52.4% received any chemotherapy, and curative intended resection was performed in 28.3%. Neoadjuvant and adjuvant therapy were performed in 4.4% and 58.7% of the cases, respectively. The median overall survival of the whole study population was 7.84 months. Patients diagnosed in the most recent period (2014–2017) had a significantly better prognosis (8.20 months (95% CI 7.97–8.43)) than patients who were diagnosed in the earlier period (2010–2013) (7.54 months (95% CI 7.31–7.70), <i>p</i> < 0.001), with an age-, sex-, and stage-adjusted hazard ratio of 0.87 (95% CI 0.85–0.9). Over time, the most pronounced treatment trends have affected patients with localized disease, with increasing frequency of resection and neoadjuvant therapy and decreasing frequency of best supportive care.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This comprehensive insight into survival and treatment of pancreatic cancer in Germany shows presumably medically beneficial therapy trends with, however, only marginal improvements in prognosis to date.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71248","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71248","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

With a rising incidence and unchanged poor prognosis, pancreatic cancer is increasingly becoming a focus of gastroenterological oncology, but there is a lack of real-world data. The aim of the current study was to investigate trends in survival and treatment patterns by analyzing German health claims data.

Methods

Pancreatic cancer patients diagnosed between 2010 and 2017 were identified from the German Pharmacoepidemiological Research Database (GePaRD, approximately 20% of the German population). Data on demographics, tumor treatment within 1 year after diagnosis, and survival were extracted.

Results

The study population comprised 23,339 patients with a median age of 74 years (IQR 66–80) and 44% with localized and 56% with metastatic disease. Overall, 52.4% received any chemotherapy, and curative intended resection was performed in 28.3%. Neoadjuvant and adjuvant therapy were performed in 4.4% and 58.7% of the cases, respectively. The median overall survival of the whole study population was 7.84 months. Patients diagnosed in the most recent period (2014–2017) had a significantly better prognosis (8.20 months (95% CI 7.97–8.43)) than patients who were diagnosed in the earlier period (2010–2013) (7.54 months (95% CI 7.31–7.70), p < 0.001), with an age-, sex-, and stage-adjusted hazard ratio of 0.87 (95% CI 0.85–0.9). Over time, the most pronounced treatment trends have affected patients with localized disease, with increasing frequency of resection and neoadjuvant therapy and decreasing frequency of best supportive care.

Conclusion

This comprehensive insight into survival and treatment of pancreatic cancer in Germany shows presumably medically beneficial therapy trends with, however, only marginal improvements in prognosis to date.

Abstract Image

查看原文本刊更多论文

胰腺癌的治疗和生存趋势：2010年至2017年诊断的23339例患者的分析

随着发病率的上升和预后不良的改变，胰腺癌越来越成为胃肠肿瘤学的焦点，但缺乏现实世界的数据。当前研究的目的是通过分析德国健康声明数据来调查生存和治疗模式的趋势。方法：从德国药物流行病学研究数据库（GePaRD，约占德国人口的20%）中确定2010年至2017年诊断的胰腺癌患者。提取人口统计学、诊断后1年内肿瘤治疗和生存率的数据。结果：研究人群包括23,339例患者，中位年龄为74岁（IQR 66-80）， 44%为局限性疾病，56%为转移性疾病。总体而言，52.4%的患者接受了化疗，28.3%的患者接受了治愈性切除。新辅助治疗和辅助治疗分别占4.4%和58.7%。整个研究人群的中位总生存期为7.84个月。最近一段时间（2014-2017）诊断的患者预后（8.20个月（95% CI 7.97-8.43））明显优于早期（2010-2013）诊断的患者(7.54个月（95% CI 7.31-7.70）。p结论：对德国胰腺癌生存和治疗的全面了解可能显示了医学上有益的治疗趋势，但迄今为止预后仅略有改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.